Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-1-12
pubmed:abstractText
Primary resectability is expected in up to 20% of pancreatic cancer patients. While most patients relapse with distant metastases, approximately 30% of patients show isolated local recurrence without evidence of distant metastases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1590-8577
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
34-40
pubmed:meshHeading
pubmed-meshheading:16407616-Aged, pubmed-meshheading:16407616-Antineoplastic Agents, pubmed-meshheading:16407616-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16407616-Cisplatin, pubmed-meshheading:16407616-Combined Modality Therapy, pubmed-meshheading:16407616-Deoxycytidine, pubmed-meshheading:16407616-Female, pubmed-meshheading:16407616-Fluorouracil, pubmed-meshheading:16407616-Humans, pubmed-meshheading:16407616-Immunosuppressive Agents, pubmed-meshheading:16407616-Leukopenia, pubmed-meshheading:16407616-Male, pubmed-meshheading:16407616-Middle Aged, pubmed-meshheading:16407616-Neoplasm Recurrence, Local, pubmed-meshheading:16407616-Pancreas, pubmed-meshheading:16407616-Pancreatic Neoplasms, pubmed-meshheading:16407616-Radiotherapy, Conformal, pubmed-meshheading:16407616-Remission Induction, pubmed-meshheading:16407616-Retrospective Studies, pubmed-meshheading:16407616-Survival Analysis, pubmed-meshheading:16407616-Thrombocytopenia, pubmed-meshheading:16407616-Time Factors, pubmed-meshheading:16407616-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
pubmed:affiliation
Clinic for Radiation Oncology, LMU University Hospital Grosshadern, Munich, Germany.
pubmed:publicationType
Journal Article